GT-04686 / Gain Therap - LARVOL DELTA

Upcoming Anticipated Milestones (The Manila Times) - "Phase 2 clinical trial of rexaceract in people with Parkinson’s disease expected to begin in Q3 2026. Final results from Phase 1b clinical study of rexaceract expected in Q4 2026. GT-04686 initial target indication expected in Q4 2026."

New P2 trial • Pipeline update • Parkinson's Disease

Also at AD/PD 2026, presented new series of novel glucocerebrosidase (GCase) allosteric modulators, represented by the advanced lead GT-04686, identified by the Company’s proprietary Magellan drug discovery platform. (GlobeNewswire) - "Novel chemical series, led by GT-04686, demonstrated activity in both in vitro and in vivo models, including increase in GCase activity and lipid substrate depletion in patient fibroblasts harboring both mutated and wildtype GBA1, as well as restoration of motor and non-motor function in an animal model of Parkinson’s disease; GT-04686 is ready for IND-enabling studies for the treatment of Parkinson’s disease and other neurological disorders."

New molecule • Preclinical • Parkinson's Disease